The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce the risk of kidney disease progression, hospitalization, and death in people with and without diabetes, regardless of their kidney function.
This article was originally published on MedicalXpress.com

